Medical Condition News

RSS

Use of oral medications for diabetes increases among Americans: Report

The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60 percent in 1997 to 77 percent in 2007, a 28 percent increase according to the latest News and Numbers from the Agency for Healthcare Research and Quality. During the same period, the proportion taking insulin to control their diabetes fell from 38 percent to 24 percent.

18 Sep 2010

Researchers identify new target for cystic fibrosis

The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.

18 Sep 2010

FDA accepts to review Aricept NDA for Alzheimer's disease

Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept, a leading medication for the treatment of Alzheimer's disease.

18 Sep 2010

FDA reviews Actos drug for bladder cancer risk

The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

18 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29, the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain.

18 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

$Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures$

Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures

Materialise announced that it would lend its considerable expertise in virtual surgical planning to researcher Dr. J. B. Jupiter, Chief Hand and Upper Extremity Service at Massachusetts General Hospital. Through an AO funded, IRB approved study, Dr. Jupiter will use SurgiCase(R) Orthopaedics to explore the advantages of computer-assisted surgery, virtual 3D planning and intra-operative use of patient-specific surgical guides in osteotomies to correct compound wrist fractures-the first research project of its kind.

17 Sep 2010

DaVita launches Kidney Awareness Run|Walks for chronic kidney disease

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today announced its launch of the 5th annual DaVita Kidney Awareness Run|Walks, a 10 city series of 5K events raising funds and awareness of CKD across the nation.

17 Sep 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

CID to provide update on Cre8 polymer-free DES program at TCT 2010

CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".

17 Sep 2010

ACTION Ontario applauds Narcotics Safety and Awareness bill

ACTION Ontario, a non-profit group advocating on behalf of chronic pain sufferers, applauds the provincial government's Narcotics Safety and Awareness bill and encourages the government to take the next step and also address the underlying issue of pain with a comprehensive strategy.

17 Sep 2010

Blood vessel growth promoting microRNA predicts diabetes: Study

For the first time, scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association.

17 Sep 2010

Shire to host panel discussion for ADHD

Shire plc, the global specialty biopharmaceutical company, has partnered with the Entertainment Industries Council (EIC) , the Lab School of Washington and other organizations in support of National Attention Deficit Hyperactivity Disorder Awareness Week to host "Fact or Fiction ADHD in America, a Capitol Hill Forum."

17 Sep 2010

Spike mat reduces muscle tension pain: Study

Spike mats do not alleviate chronic pain. Nor do they lead to a better night's sleep. But pain sufferers who have tested a spike mat did experience a measurable reduction in the worst peaks of pain. This is shown in a research study performed at Karlstad University in Sweden.

17 Sep 2010

Wounded Warrior Project applauds introduction of traumatic brain injury bill

Wounded Warrior Project applauds Congressman Tim Walz (D – MN) for introducing legislation today in the U.S. House of Representatives that would ensure fuller lives for warriors who sustained severe traumatic brain injuries (TBI) in Iraq and Afghanistan, and urges speedy action on this measure.

17 Sep 2010

Society for Vascular Nursing partners with local hospitals to create P.A.D awareness

Approximately 9 million Americans have peripheral arterial disease (P.A.D.), a common and dangerous vascular disease that can lead to heart attack, stroke, amputation and death. Unfortunately, many with the disease do not even know they have it. September is P.A.D. Awareness Month, and the P.A.D. Coalition and the Society for Vascular Nursing are joining forces with local hospitals to inform Americans about the risk factors, warning signs and consequences of P.A.D.

17 Sep 2010

Vital Therapies expands SILVER clinical trial to Middle East

Vital Therapies, Inc., is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia in the further expansion of its SILVER clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure.

17 Sep 2010